Top

Published in:

01-09-2014 | Original Paper

Willingness to Use HIV Pre-Exposure Prophylaxis Among Opiate Users

Authors: Michael Stein, Portia Thurmond, Genie Bailey

Published in: AIDS and Behavior | Issue 9/2014

Abstract

Few studies of pre-exposure prophylaxis (PrEP) to prevent HIV infection have focused on drug users. Between February to September 2013, we asked 351 opiate injectors entering detoxification treatment about HIV risk, knowledge about PrEP, and willingness to use a once daily PrEP pill under one of two randomly assigned effectiveness scenarios—40 % (low) or 90 % (high) effective in reducing HIV risk. Participants were 70 % male and 87 % non-Hispanic White. Only 7 % had heard of a drug to reduce HIV risk, yet once informed, 47 % would be willing to take such a pill [35 % of those in the low effectiveness scenario and 58 % in the high group (p < 0.001)]. Higher perceived HIV risk was associated with greater willingness to take medication. Increasing knowledge of PrEP and the rate of HIV reduction-effectiveness promised will influence its use among targeted high-risk drug users.

Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520–9.PubMedCentralPubMedCrossRef

Centers for Disease Control and Prevention. HIV Surveillance Report, 2008, vol 20 Atlanta, US, 2010.

Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS One. 2011;6(8):e17502.PubMedCentralPubMedCrossRef

Coyle SL, Needle RH, Normand J. Outreach-based HIV prevention for injecting drug users: a review of published outcome data. Public Health Rep. 1998;113(Suppl 1):19–30.PubMedCentralPubMed

Metzger DS, Navaline H. HIV prevention among injection drug users: the need for integrated models. J Urban Health. 2003;80(43):59–66.

Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep. 1998;113(Suppl 1):75–80.PubMedCentralPubMed

Avins AL, Lindan CP, Woods WJ, et al. Changes in HIV-related behaviors among heterosexual alcoholics following addiction treatment. Drug Alcohol Depend. 1997;44(1):47–55.PubMedCrossRef

Gossop M, Marsden J, Stewart D, Treacy S. Reduced injection risk and sexual risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care. 2002;14(1):77–93.PubMedCrossRef

Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.PubMedCentralPubMedCrossRef

10.

Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60(3):65–8.

11.

Update to Interim Guidance for Preexposure Prophylaxis. (PrEP) for the Prevention of HIV Infection: prEP for injecting drug users. MMWR Morb Mortal Wkly Rep. 2013;62(23):463–5.

12.

Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedCentralPubMedCrossRef

13.

Marrazzo JM, Ramjee G, Nair G, et al., editors. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir-emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013); 2013; Atlanta, GA.

14.

Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr. 2012;59(4):354–9.PubMedCrossRef

15.

Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.PubMedCrossRef

16.

Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.PubMedCentralPubMedCrossRef

17.

Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.PubMedCrossRef

18.

Baral SD, Stromdahl S, Beyrer C. The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. Curr Opin HIV AIDS. 2012;7(6):563–8.PubMedCrossRef

19.

Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health: National findings. NSDUH Series H-34 DHHS Publication No. SMA 08-4343 ed. Rockville: Office of Applied Studies; 2008.

20.

Stein MD, O’Sullivan PS, Ellis P, Perrin H, Wartenberg A. Utilization of medical services by drug abusers in detoxification. J Subst Abuse. 1993;5(2):187–93.PubMedCrossRef

21.

Substance Abuse and Mental Health Services Administration. The DASIS Report: Admissions for detoxification, 2001. Rockville: Office of Applied Studies; 2004.

22.

Center for Substance Abuse Treatment. TIP 19: Detoxification From Alcohol and Other Drugs: Treatment Improvement Protocol (TIP) Series 19; DHHS Publication No. (SMA) 95-3046. SAMHSA/CSAT Treatment Improvement Protocols. Rockville: Substance Abuse and Mental Health Services Administration; 1995.

23.

Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: National Findings. NSDUH H-32 DHHS Publication No. SMA 07-4293 ed. Rockville: Office of Applied Studies; 2007.

24.

Barash EA, Golden M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDS. 2010;24(11):689–91.PubMedCrossRef

25.

Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548–55.PubMedCentralPubMedCrossRef

26.

Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R. Attitudes and program preferences of african-american urban young adults about pre-exposure prophylaxis (PrEP). AIDS Educ Prev. 2012;24(5):408–21.PubMedCrossRef

27.

Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, Leibowitz AA. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care. 2011;23(9):1136–45.PubMedCentralPubMedCrossRef

28.

Liu AY, Kittredge PV, Vittinghoff E, et al. Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr. 2008;47(2):241–7.PubMedCrossRef

29.

Mansergh G, Koblin BA, Colfax GN, McKirnan DJ, Flores SA, Hudson SM. Preefficacy use and sharing of antiretroviral medications to prevent sexually-transmitted HIV infection among US men who have sex with men. J Acquir Immune Defic Syndr. 2010;55(2):e14–6.PubMedCrossRef

30.

Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50(1):77–83.PubMedCentralPubMedCrossRef

31.

Mehta SA, Silvera R, Bernstein K, Holzman RS, Aberg JA, Daskalakis DC. Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City. Sex Transm Infect. 2011;87(4):344–8.PubMedCrossRef

32.

Wingood GM, Dunkle K, Camp C, et al. Racial differences and correlates of potential adoption of preexposure prophylaxis: results of a national survey. J Acquir Immune Defic Syndr. 2013;63(1):S95–101.PubMedCentralPubMedCrossRef

33.

Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010;14(4):731–47.PubMedCrossRef

34.

Whiteside YO, Harris T, Scanlon C, Clarkson S, Duffus W. Self-perceived risk of HIV infection and attitudes about preexposure prophylaxis among sexually transmitted disease clinic attendees in South Carolina. AIDS Patient Care STDS. 2011;25(6):365–70.PubMedCrossRef

35.

Aghaizu A, Mercey D, Copas A, Johnson AM, Hart G, Nardone A. Who would use PrEP? Factors associated with intention to use among MSM in London: a community survey. Sex Transm Infect; 2012.

36.

Ajzen I, Fishbein M. Understanding attitudes and predicting social behavior. Englewood Cliffs: Prentice Hall; 1980.

37.

Fisher WA, Fisher JD, Rye BJ. Understanding and promoting AIDS-preventive behavior: insights from the theory of reasoned action. Health Psychol. 1995;14(3):255–64.PubMedCrossRef

Title: Willingness to Use HIV Pre-Exposure Prophylaxis Among Opiate Users
Authors: Michael Stein
Portia Thurmond
Genie Bailey
Publication date: 01-09-2014
Publisher: Springer US
Published in: AIDS and Behavior / Issue 9/2014
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-014-0778-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2014

Preferences for Daily or Intermittent Pre-exposure Prophylaxis Regimens and Ability to Anticipate Sex Among HIV Uninfected Members of Kenyan HIV Serodiscordant Couples

Adherence to Rectal Gel Use Among Mainly Ethnic Minority Young Men Who have Sex with Men During A 3-Month Placebo Gel Trial: Implications for Microbicide Research

HIV Providers’ Perceived Barriers and Facilitators to Implementing Pre-exposure Prophylaxis in Care Settings: A Qualitative Study

Effects of Messaging About Multiple Biomedical and Behavioral HIV Prevention Methods on Intentions to use Among US MSM: Results of an Experimental Messaging Study

Factors Influencing HIV Serodisclosure Among Men Who Have Sex with Men in the US: An Examination of Online Versus Offline Meeting Environments and Risk Behaviors

Pre-Exposure Prophylaxis Accessibility Research and Evaluation (PrEPARE Study)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials